I get your point, and this may look good on paper at least. However, I expect the boards of CSL and RAC would be dealing with completely different types of problems and therefore their makeup and skill set would potentially differ significantly. Also, RAC having a board member from "Big Pharma" may not be ideal at this stage from a deal-making perspective.
I get your point, and this may look good on paper at least....
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.63 |
Change
-0.050(2.98%) |
Mkt cap ! $284.5M | |||
| Open | High | Low | Value | Volume |
| $1.67 | $1.67 | $1.61 | $149.0K | 92.00K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1501 | $1.64 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.66 | 8646 | 3 |
View Market Depth
| Last trade - 14.54pm 09/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |